α7 nAChR Selective Benzamide for CNS Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Nicotinic compounds often exhibit undesirable side effects due to non-specific binding to multiple nAChR subtypes, limiting their therapeutic utility, particularly in targeting the α7 subtype without affecting muscle and ganglionic nAChR subtypes.
Innovation Solution
Development of (2S,3R)—N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide, which exhibits high affinity and selectivity for the α7 nAChR subtype with low affinity for α4β2, ganglionic, and muscle subtypes, allowing for therapeutic modulation of α7 nAChRs without unwanted side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If nicotinic compounds are used to target multiple nAChR subtypes, then broad therapeutic coverage is achieved, but side effects increase due to non-specific binding
Solution Approach 1:
The patent segments the nAChR receptor family into specific subtypes (α4β2, α7, α3β4, muscle types) and designs compounds that selectively target individual subtypes rather than binding broadly to all nAChR subtypes. This segmentation approach allows therapeutic intervention at specific receptor levels, achieving targeted efficacy while avoiding off-target side effects.
Solution Approach 2:
The patent applies local quality by creating compounds with differentiated binding properties for different nAChR subtypes. The molecular structure is optimized to exhibit high affinity for specific subtypes (e.g., α4β2 or α7) while maintaining low affinity for others, thereby localizing the therapeutic action to specific receptor populations and minimizing systemic side effects.
2Adaptability or versatility
If compounds bind to muscle and ganglionic nAChR subtypes, then broad receptor coverage is achieved, but therapeutic utility is limited due to unwanted side effects
Solution Approach 1:
The patent extracts the desired therapeutic function from the broader class of nicotinic compounds by isolating and optimizing for specific subtype selectivity. Rather than relying on broad-spectrum binding, the invention extracts and enhances the ability to discriminate between nAChR subtypes, taking out only the necessary binding interaction with target subtypes while eliminating unwanted interactions with muscle and ganglionic subtypes.
Solution Approach 2:
The patent employs parameter changes by systematically modifying molecular structure parameters (functional groups, stereochemistry, substituent positions) to tune binding affinity and selectivity profiles. These parameter adjustments enable the compounds to achieve high affinity for desired subtypes while maintaining low affinity for muscle and ganglionic subtypes, thereby improving therapeutic reliability.
3Quantity of substance
If high affinity binding to multiple nAChR subtypes is achieved, then broad pharmacological activity is obtained, but selectivity for specific subtypes is reduced
Solution Approach 1:
The patent applies local quality by designing compounds with heterogeneous binding characteristics across different nAChR subtypes. The molecular structure incorporates specific features that create high affinity interactions with target subtypes (through complementary binding sites, hydrogen bonding, hydrophobic interactions) while simultaneously creating steric or electronic barriers that prevent binding to non-target subtypes, thereby achieving both high affinity and high selectivity.
Solution Approach 2:
The patent employs asymmetry in the molecular design to achieve subtype selectivity. The compounds feature asymmetric structural elements (chiral centers, non-symmetric substituent patterns) that match the asymmetric binding pockets of specific nAChR subtypes. This asymmetric design allows high affinity binding to the correct subtype while preventing binding to subtypes with different spatial arrangements, thereby resolving the contradiction between affinity and selectivity.
Data Source
AI summary
The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).